Introduction
Injectable formulations of 5-fluorouracil (5-FU) and its synergistic biomodulator leucovorin (LV; calcium folinate) form the cornerstone of many current colorectal cancer chemotherapy regimens [1, 2] . We have previously reported the development of all-in-one injectable pH neutral formulations of 5-FU and LV, which overcome the physical/chemical incompatibilities between 5-FU and LV and otherwise prevent a single-solution intravenous administration. This was achieved by incorporating either sulfated b-cyclodextrin (S-b-CD; 7-14 sulfate groups) or a 2-(hydroxypropyl)-b-cyclodextrin (HP-b-CD) as excipients [3] . These formulations significantly reduce phlebitis, thus improving the tolerability of current intravenous 5-FU regimens while maintaining all cytotoxic properties in vitro and in animal tumor models [4] .
In addition to their solubilizing properties, other significant benefits may also be gained through the use of S-b-CDs in chemotherapy formulations as they are known to show heparin-like anticoagulant activity [3, [5] [6] [7] . Heparins are routinely used for the treatment of thromboembolic complications in cancer patients, which are a result of the hyperactivation of the coagulation cascade [8, 9] . When used in conjunction with chemotherapeutics, heparins have been reported to improve the survival outcomes for cancer patients in some [10] [11] [12] but not all trials, which may be related to stage and/or type of cancer [13] . This may be because the cancer metastasis process requires coagulation [14, 15] . The heparins may also influence a number of cellular processes such as tumor cell growth through inhibition of heparin-binding growth factors, and angiogenesis, and thereby ultimately affect cancer progression [8, 10] .
Despite the potential benefits, a summary of animal model studies by Neirs et al. [12] concluded that high doses of heparin administered at length are required to significantly reduce metastasis, whereas low doses of heparins administered as part of short administration regimens were ineffective. Long-term administration of high-dose heparin is considerably limited as patients often experience hemorrhagic complications because of the systemic inhibition of coagulation [16] [17] [18] [19] . As S-bCDs are associated with reduced systemic anticoagulant activity [6] , these excipients not only provide a valuable alternative to heparins but, when incorporated into Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.anti-cancerdrugs.com).
chemotherapeutic drug formulations, may also improve the survival outcomes for cancer patients.
We have previously reported that a 5-FU formulation incorporating 172 mg/ml of S-b-CD [termed FD(S)] not only retained anticoagulant properties [3] but was also shown to reduce tumor growth more effectively than 5-FU/LV in an orthotopic human xenograft tumor model in mice [4] . It is possible that the improved efficacy of FD(S) is partly because of the anticoagulation properties of the S-b-CD component of the formulation [3] . However, S-b-CDs have also been reported to modify a number of processes involved in angiogenesis in a concentration-dependent manner [5, 20, 21] . As the maximum tolerated dose (MTD) of FD(S) represents a systemic concentration of S-b-CD of B2 mmol/l/dose at which no bleeding problems were observed [4] , it is conceivable that the improved anticancer effect of FD(S) compared with 5-FU/LV at the MTD is in part also because of the antiangiogenesis properties of S-b-CD.
Angiogenesis is a complex process, dependent on the interactions of various host and tumor cells that involves endothelial cell (EC) adhesion, proliferation, migration, and differentiation into tubule structures [22, 23] . As metastasis is the major cause of treatment failure in cancer patients [14, 15] , the therapeutic inhibition of angiogenesis could therefore prove critical to the prevention of regrowth of tumor masses treated with cytotoxic drug regimens and to limiting metastases [24] . To this end, FD(S) may induce a synergistic effect, whereby the S-b-CD component inhibits angiogenesis and thus metastasis in addition to the cytotoxic action of 5-FU/LV on tumor cells. The purpose of the current study was thus to determine the effect of S-b-CD and FD(S) on the process of angiogenesis at a cellular level, which involved analysis of the proliferation, migration, and reorganization of ECs into tubule structures. Confirmation of this effect was also ascertained using ex-vivo assays. As angiogenesis is a prognostic factor for metastatic cancer [25] , results showing an antiangiogenic effect of S-b-CD in FD(S) could lead to further development of cytotoxic or other anticancer drugs incorporating this compound into their formulations.
Materials and methods

Formulation preparation
Sterile stock solutions of FD(S), S-b-CD, and HP-b-CD were prepared as described previously [3] . Pharmaceutical-grade 5-FU solution (ONCO-TAIN 5-FU Injection, 50 mg/ml) was obtained from Mayne Pharma Pty. Ltd (Salisbury, South Australia). LV solution (LV Calcium Injection USP, 10 mg/ml) was obtained from Hospira Australia Pty. Ltd (Mulgrave, Australia). For 5-FU/LV, the components were prepared immediately before use as described by Locke et al. [3] . S-b-CD sodium salt (2206.5 g/mol, with B9-12 sulfate groups per cyclodextrin molecule) and HP-b-CD (1540 g/mol) were obtained from Sigma-Aldrich (St Louis, Missouri, USA).
Cell lines and culture conditions
The SV40 transformed endothelial cell (SVEC4-10) line and primary human vascular endothelial (HUV-EC-C) line were purchased from the American Type Culture Collection, distributed by Cryosite (Sydney, Australia), and cultivated as recommended by the supplier. SVEC4-10 cells retain the morphological and functional characteristics of primary ECs but proliferate indefinitely without the specific growth factor requirements of primary ECs [26] . Cells were routinely cultured in cell line-specific media at 371C in a 95% humidified atmosphere, containing 5% CO 2 . SVEC4-10 cells were grown in Dulbecco's Modified Eagle Medium (Invitrogen, Life Technologies Australia Pty. Ltd, Mulgrave, Victoria, Australia) supplemented with 5% (v/v) heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich). The HUV-EC-C cells were grown in a HAMS/F12K nutrient mixture (Kaighn's modification) containing 0.1 mg/ml unfractionated heparin (Sigma-Aldrich), 0.03 mg/ml EC growth supplement (Sigma-Aldrich), and 2.5 g/l sodium bicarbonate, and supplemented with 10% (v/v) heatinactivated FBS (Sigma-Aldrich). All tissue culture flasks and cell assay plates used for the routine culture of HUV-EC-C cells (passage 3-6) were coated overnight with a 1% (v/v) gelatin solution (Sigma-Aldrich).
xCELLigence EC proliferation assays
The effect of 5-FU, FD(S), and S-b-CD on EC proliferation was determined using the xCELLigence System (Roche Applied Science, Indianapolis, Indiana, USA) in specialized 16-well E-16 plates. Following the addition of 100 ml of cell culture media to the wells, the cell lines were seeded at 5000 cells/well in a volume of 80 ml. The cells were allowed to settle for 30 min at room temperature before being incubated at 371C for 24 h. Varying concentrations of the compounds in 20 ml sterile water were then added and the plate was again incubated at 371C for 72 h. Comparisons were made with untreated cells that received 20 ml of sterile water. Background wells containing media without cells were included. The adhesion, spreading, and proliferation of cells were measured as a dimensionless parameter termed cell index (CI) in real time. CI is derived from the relative change in measured electrical impedance, whereby electrical impedance represents the presence and spread of adherent cells. Real-time data were accumulated every 15 min and graphed using the RTCA-DP Software (version 1.2.1), supplied with the xCELLigence System.
xCELLigence EC invasion/migration assays
The effect of S-b-CDs and FD(S) on SVEC4-10 and HUV-EC-C cell invasion/migration was analyzed with the xCELLigence System using specialized two-layer cell invasion and migration plates (CIM plates), in which a porous membrane (pore size 8 mm) separates the upper and lower wells. Cell culture media (160 ml) were added to the lower wells of the CIM plates, omitting the test compounds. The lower wells contained the chemotactic control of FBS-containing media or serum-free (SF) media for basal-level invasion/migration. Following assembly of the CIM plate, 25 ml of SF media were dispensed into the upper wells and the plate was incubated at 371C for 1 h to allow for equilibration of the membrane. For HUV-EC-C cells, the upper CIMplate wells were precoated with 25 ml Geltrex Basement Membrane Matrix gel (Invitrogen, Life Technologies Australia Pty. Ltd) to allow cell adhesion and spreading. During this time, the cells (HUV-EC-C cells had been deprived of serum for the previous 12 h) were harvested and resuspended in SF media and then seeded into the upper wells at an optimized count of 40 000 cells/well in a volume of 90 ml. Varying concentrations of S-b-CDs and FD(S) that were deemed nontoxic by cell proliferation assays, in 10 ml SF media, were added to the upper wells containing cell suspensions. Untreated cells received 10 ml SF media alone. The plate was incubated at 371C and the migration of cells across the membrane into the lower wells was measured as CI in real time over 12 h. Real-time data were accumulated and graphed as described above.
In-vitro angiogenesis inhibition assays
The effect of S-b-CD, alone and in the FD(S) formulation, on the degree of EC tubule formation was examined using an in vitro Angiogenesis Assay Kit (Cayman Chemical Company, Ann Arbor, Michigan, USA) in flatbottomed 24-well microplates coated with Geltrex Basement Membrane Matrix gel (Invitrogen, Life Technologies Australia Pty. Ltd) as a supportive matrix. Before cell seeding, a grid was drawn on the underside of the wells using a fine marker pen to divide the area into quadrants and the wells were coated with 95 ml Geltrex. To solidify the gel, the plate was warmed to 371C for 30 min. Cell suspensions were prepared in culture medium in the absence or presence of 0.3 mmol/l JNJ-10198409 angiogenesis inhibitor as a negative control or S-b-CD or FD(S) at varying concentrations. Cells were seeded at an optimized density of 42 000 cells/cm 2 (80 000 cells/well) in a volume of 400 ml. Plates were incubated at 371C for 7 h to allow tubule formation.
At the conclusion of incubation, cell morphology and the degree of tubule formation were visualized using an inverted light microscope and an inverted epifluorescence microscope with images captured using a mounted digital camera (Nikon Instruments Inc., Melville, New York, USA) and a mounted Leica DC500 camera (Leica Microsystems, Wetzlar, Germany), respectively. Four photographs (Â 4 magnification) were taken in each quadrant of duplicate treatment wells using an inverted light microscope, for manual scoring of tubule formation, followed by four epifluorescence photographs (Â 10) of calcein AM-stained cells. For manual scoring, multiple scorers blinded to the allocated treatment counted the number of fully enclosed vacuoles formed by tubule branches in eight photographs per treatment, four from each duplicated well; vacuoles that breached the edge of the photograph were not counted. Cell and tubule network morphology was also scored using a numerical ranking system from 0 to 3, adapted from the Millicell m-Angiogenesis Inhibition Assay Protocol (Millipore, Billerica, Massachusetts, USA). Briefly, a score of 0 = mostly undifferentiated cells, no/little tubule network or sprouting cells noted; 1 = sprouting of new tubules visible with large pockets of undifferentiated cells between them; 2 = sprouting of new tubules visible with small pockets of undifferentiated cells between them; and 3 = expansive tubule networks with consistently elongated cells.
Rat aorta ring assay
The rat aorta ring assay method and culture medium were essentially the same as for the human angiogenesis assay as described previously in Brown et al. [27] , with the addition of aprotinin to prevent fibrinolysis. Also, the heat-inactivated FBS was not passed down a heparinsepharose column and assays were performed in 48-well culture plates (Costar, Cambridge, Massachusetts, USA).
Descending thoracic aortas were excised from 3-9-month-old female Fischer F344 rats, rinsed in Hank's balanced salt solution containing 2.5 mg/ml amphotericin B (Sigma-Aldrich), and cross-sectioned at 1 mm intervals using a dissecting microscope (Olympus SZH-ILLD, Hamburg, Germany). Five hundred microliters of 3 mg/ml fibrinogen (bovine plasma; Calbiochem, La Jolla, California, USA) in SF medium 199 (Gibco; LifeTechnologies, Grand Island, New York, USA) was added to each well with 5 mg/ml of aprotinin in PBS (Sigma-Aldrich). One vessel fragment was placed in the center of the well and 15 ml of bovine plasma thrombin (50 NIH U/ml in 0.15 mol/l NaCl; Sigma-Aldrich) was added to the well and mixed rapidly with the fibrinogen. After embedding of the vessel fragment in the fibrin gels and clot formation, 0.5 ml/well of medium M199 (Gibco; LifeTechnologies), supplemented with 20% FBS (SigmaAldrich), 0.1% E-aminocaproic acid (Sigma-Aldrich), 1% L-glutamine (100 mmol/l; Sigma-Aldrich), 1% amphotericin B (250 mg/ml; Sigma-Aldrich), and 0.6% gentamycin (40 mg/ml; Sigma-Aldrich), was added. S-b-CD was made at 100 times the final concentrations required in ddH 2 O, sterile filtered, and added to the medium. Each treatment was performed in sextuplet. Control cultures received medium without the test substance. PI-88, an antiangiogenic sulfated polysaccharide [28] , was included as a positive vessel growth inhibitor control. Vessels were cultured at 371C in 5% CO 2 in air for 5 days with a medium with/without test compound change on day 4. Vessel growth was quantified manually under Â 40 magnification (Nikon TMS Microscope; Nikon Instruments Inc.) on day 5, with growth being estimated as the percentage of the field (Â 40) around the vessel fragment that was occupied by vessel outgrowths. Typical new vessel growth in control wells was B80% by day 5.
Chick embryo CAM collagen onplant assay
The ex ovo chick embryo chorioallantoic membrane (CAM) collagen onplant assay protocol utilizes the highly vascularized CAM as an experimental model capable of investigating angiogenesis [29] . Fertile Barter Brown Crossbreed chicken eggs were obtained from Barter and Sons Hatchery (Luddenham, Australia). To initiate embryogenesis, the eggs were placed in a rotary incubator at 37.81C and 60% relative humidity for 3 days. At embryonic day 3, the CAM was 'dropped' from the inside of the shell, as described in Storgard et al. [29] . The shell was carefully cut open under sterile conditions using an engraving power tool, allowing the entire contents of the eggs to be transferred to presterilized plastic weighing boats with slanted walls (Lomb Scientific, Taren Point, New South Wales, Australia). The contents were covered with square Petri dish lids and the containers were placed in a stationary incubator at 37.81C and 90% relative humidity for another 3 days to allow the CAM to develop. At embryonic day 6, collagen onplants were prepared using autoclaved 4 Â 4 mm nylon mesh squares of 180 mm grid size (Sefar AG, Heiden, Switzerland). Onplants were assembled by overlaying two mesh squares in Petri dishes, which were lined with Parafilm and sterilized with ethanol. Test compounds were diluted from stock solutions in 10 Â PBS and added to neutralized 3 mg/ml collagen solutions prepared from rat-tail collagen (SigmaAldrich) as described in Deryugina and Quigley [30] . The final collagen solutions contained either PBS alone (control), 0.01 mmol/l JNJ-10198409, or 0.3 mmol/l S-b-CD, diluted from a 200 mmol/l stock solution. This concentration of S-b-CD was chosen because it falls within the range of concentrations that inhibit EC migration and is an achievable systemic concentration after a MTD dose administration in mice [4] . The final collagen solutions (30 ml) were placed on top of the mesh squares and the onplants were allowed to polymerize at 371C for 1 h and then solidify at room temperature. The onplants were topically positioned on the CAM in areas containing fine vascular networks. Individual embryos received four onplants, containing one of each of the four treatments, in different quadrants of the embryo. Onplant-bearing embryos were incubated for an additional 96 h at 37.81C and 90% relative humidity in a HERAcell stationary incubator (Thermofisher Scientific, Waltham, Massachusetts, USA). At this time, the extent of vascularization within the onplant was visualized using a stereomicroscope, with a Moticam 1000 live imaging camera attached (Motic, Richmond, British Columbia, Canada).
Statistical analysis
Statistical differences between the effects of test compounds compared with control (vehicle only) treatments were determined using an unpaired Student's t test (GraphPad Prism V 5.1; GraphPad Software Inc., San Diego, California, USA). P-values less than 0.05 were considered statistically significant.
Results
S-b-
To determine the effect of S-b-CD both alone and within FD(S) on EC proliferation over time and to establish noncytotoxic concentrations for subsequent assays, realtime live-cell kinetic assays were used. In the absence of S-b-CD, SVEC4-10 cells grew exponentially up to 40 h after cell seeding and then reached a plateau (Fig. 1a,  untreated) . The addition of 20 mmol/l S-b-CD during logphase growth (24 h after seeding) caused an initial steep, and then continued to decrease in CI values to zero impedance relative to the control within 48 h of treatment (Fig. 1a) . This indicates a complete loss of cells, which is suggestive of either a potent cytotoxic effect and/or loss of cell adhesion. At concentrations less than or equal to 4 mmol/l, CI values were essentially similar to those obtained with untreated cells over the time frame of the assay (Fig. 1a , P > 0.05), indicating that SVEC4-10 EC proliferation was unaffected by S-b-CD at these concentrations. In other experiments, CI levels were partially reduced within 24 h after the addition of 10 mmol/l S-b-CD, with full recovery attained thereafter (data not shown). S-b-CD at concentrations less than or equal to 4 mmol/l had no growth-arresting affect on SVEC4-10 cells after 72 h of treatment was confirmed using a standard endpoint cell proliferation assay (data not shown), as shown previously for other proliferative cell types [3] . SVEC4-10 ECs treated with FD(S) encompassing a concentration range of 5-FU previously shown to be cytotoxic after 72 h in a variety of cancer cell lines [3] , showed time-dependent cytotoxic effects (Fig. 1b) . S-b-CD concentrations within the FD(S) formulation corresponded to less than 1 mmol/l, indicating that the cytotoxic effects observed were because of the 5-FU component of the formulation. As expected for 5-FUmediated cytotoxicity, dose-dependent cytotoxic effects were apparent 48 h after compound addition, with maximal effects obvious by 72 h after FD(S) treatment (Fig. 1b) . A 50% inhibitory concentration (IC 50 ) value of B20 mmol/l was calculated by the RTCA-DP Software (ACEA Biosciences Inc., San Diego, California, USA) The long population doubling time of HUV-EC-C cells (6-7 days) precluded testing the potential cytotoxic effect of FD(S) as the cells did not proliferate under the time frame and conditions of these experiments (data not shown). S-b-CD over the concentration range 2.5-0.3 mmol/l exerted no effect on HUV-EC-C cell proliferation (data not shown).
S-b-CD alone and within FD(S) inhibits EC migration
The migratory function of ECs is essential for angiogenesis. S-b-CD over the concentration range 4 mmol/l-1.28 mmol/l inhibited the migration of SVEC4-10 ECs toward FBS as the chemoattractant in the lower chambers ( Fig. 2a ; P < 0.01 at 12 h for all treatments compared with the control). At the highest concentration of S-b-CD, CI values were equivalent to basal CI values (SF media in the lower chambers). The inhibitory effect of S-b-CDs on SVEC4-10 migration was reduced at the lower concentrations (0.8 mmol/l-1.28 mmol/l), with no apparent dose response in this range (Fig. 2a) . The reason for this lack of dose dependence is unclear. SVEC4-10 EC migration was mildly stimulated (B12% above the level of the positive control) at very low-range concentrations of Sb-CDs (r 0.5 mmol/l) (data not shown). The inhibitory effect of S-b-CD on SVEC4-10 cell migration was uncompromised within FD(S) (equivalent S-b-CD concentration range 4 mmol/l-1.25 mmol/l) ( Fig. 2b ; P < 0.01 at 12 h for all treatments compared with the control). The FD(S) has no cytotoxic effect within the time frame of the migration assays (12 h) (refer to Fig. 1b) and so the antimigratory effect can be attributed to the S-b-CD component. Fig. 3b ; P < 0.01 at 12 h for all treatments compared with the control). Thus, incorporation of S-b-CD in FD(S) did not compromise the inhibition of HUV-EC-C cell invasion and migration. The potential requirement for an invasion step through the GELTREX coating on membranes necessary for HUV-EC-C cell attachment and spreading in the assay chambers (not required for SVEC4-10 ECs) before migration may have accounted for the small concentration effect difference between the HUV-EC-C and the SVEC4-10 ECs.
S-b-CD inhibits spontaneous tubule formation by HUV-EC-C cells at therapeutic doses of FD(S)
The culture of ECs on a supportive matrix with growth factors results in morphological changes and the formation of tubule structures that replicate vasculature, a phenomenon known as spontaneous angiogenesis [31] . This was shown by the formation of expansive tubule networks when HUV-EC-C cells were grown on Geltrex with growth factor-containing media (Fig. 4a and Table 1 ). Incubation of HUV-EC-C cells in the presence of the angiogenesis inhibitor control JNJ-10198409 reduced the formation of tubule networks, with small pockets of undifferentiated cells observed between tubule branches ( Fig. 4b and Table 1 ).
At 15.6 mmol/l S-b-CD alone (Fig. 4c ) and in FD(S) (Fig. 4d) , HUV-EC-C cell morphology was similar to that after JNJ-10198409 treatment, with pockets of undifferentiated cells between tubule branches observed but with no significant difference in the number of fully enclosed vacuoles formed compared with the media control ( Table 1) . Cells remained undifferentiated, with no tubule network formation evident after treatment with 1.56 mmol/l S-b-CD alone (Fig. 5e ) and in FD(S) (Fig. 5f ). This represented highly significant inhibition of spontaneous angiogenesis as vacuole formation was reduced by more than 96% (Table 1 ) compared with the media control. This inhibitory effect was because of the S-b-CD component of FD(S) as an equivalent concentration of nonsulfated HP-b-CD, either alone or incorporated into a separate 5-FU formulation termed FD(HP) [3] , did not affect the degree of tubule formation relative to the media control ( Supplementary  Fig. 2 , http://links.lww.com/ACD/A8). Within the time frame of these experiments (7 h), changes in cell numbers because of treatment with 1.56 mmol/l S-b-CD were not expected (see above).
S-b-CD prevents the formation of new vasculature ex vivo
The rat aortic ring assay, which measures angiogenic sprouting from normal blood vessels ex vivo, was used to confirm the inhibitory effect of S-b-CD on angiogenesis. This response does not require the addition of exogenous growth factors and provides a convenient system for testing compounds for their ability to inhibit microvessel outgrowth [27] . S-b-CD at 3.2, 1.6, and 0.8 mmol/l significantly inhibited new vessel outgrowth by 85, 55, and 52%, respectively (Table 2 ). Although the difference between the control and 0.2 and 0.1 mmol/l S-b-CD treatment was significant (Table 2) , more than 50% inhibition of new vessel growth in the assay is required for a compound to be considered to have true antiangiogenic properties [27] .
The ex ovo chick embryo CAM collagen onplant assay was also used to further confirm the inhibitory effect of S-b-CD on angiogenesis qualitatively. PBS-containing control onplants did not induce the advancement of fine vessels toward the onplant after 4 days as expected (Fig. 5a) , although fine vessels branching from preexisting major vessels within the onplant site were observed. Onplants containing the inhibitory control JNJ-10198409 prevented the formation of new fine vasculature over the 4-day treatment period and a fine vessel avascular zone was evident within the onplant area (Fig. 5b) . Onplants containing 0.3 mmol/l S-b-CDs also prevented the formation of new vasculature over the 96-h treatment period (Fig. 5c) . Observations at higher magnification showed a 2-3 mm avascular region free of fine blood vessels within the onplant area ( Supplementary Fig. 3 , http://links.lww.com/ACD/A8).
Discussion
The results of the current study confirm the inhibitory potential of S-b-CD alone on angiogenesis in vitro and ex ovo and, importantly, that these antiangiogenesis properties are maintained in FD(S). At and below concentrations of S-b-CD that are achievable after systemic administration of FD(S) doses that reduce tumor growth (< 2 mmol/l S-b-CD) [4] , FD(S) markedly inhibited spontaneous tubule formation of HUV-EC-C cells in vitro in a dose-dependent manner. This effect appears to be mediated through inhibition of invasion/migration of differentiated ECs. The lack of effect of a nonsulfated b-CD on in-vitro angiogenesis as well as EC migration (data not shown) confirmed the necessity of sulfate groups for the antiangiogenic activity of S-b-CDs [5, 21] . Water-soluble sulfated cyclodextrins show low systemic toxicity in animals [6] , and high concentrations of S-b-CD (up to 1 mmol/l) are not cytotoxic against a variety of human carcinoma cell lines [3] or human vascular smooth muscle cells [20] . This was confirmed for the transformed EC cell Table 2 Effect of S-b-CD on angiogenic sprouting from normal blood vessels using the in-vitro rat aorta ring assay line SVEC4-10 at concentrations of S-b-CD r 4 mmol/l. As reported for carcinoma cell lines [3] , FD(S) encompassing these nontoxic S-b-CD concentrations was cytotoxic against SVEC4-10 ECs, reflective of the antimetabolite activity of 5-FU achieved in proliferative cells [3] . Thus, together with the potential anticoagulant effects of S-b-CD in the metastatic process, we propose that the beneficial effect of FD(S) over 5-FU alone in tumor models was because of the synergistic action of (a) 5-FU toxicity against proliferating tumor cells as well as ECs stimulated to proliferate during the angiogenic process and (b) the immediate anti-invasive/migratory effect of S-b-CD on both differentiated and undifferentiated ECs. A detailed study to examine all of these effects of FD(S) in tumor models is now warranted.
Angiogenesis involves the rearrangement of localized ECs to form tubule structures [32] , following the recruitment and migration of ECs by chemotaxis [33, 34] . The inhibitory effect on in-vitro EC tubule formation and migration of S-bCDs is possibly linked to the ability of S-b-CDs to interact with and inhibit the activity of key growth factors present in the FBS [35] , particularly basic fibroblast growth factor (bFGF), [20, 36] . Low-molecular-weight heparins and S-bCDs alike bind with high affinity to bFGF [20, 37, 38] and, despite showing no cytotoxic potential, S-b-CDs are able to inhibit smooth muscle cell proliferation induced by bFGF [38] . In our experiments, S-b-CD did not significantly inhibit EC proliferation despite considerably reducing EC migration and tube formation. A possible explanation for this finding is that the batch of FBS used in our experiments contained mitogenic factors that are not affected by S-b-CD. Nonetheless, EC migration and differentiation were affected by S-b-CD and these processes were not considerably diminished by FD(S).
We also confirmed the effect of S-b-CDs on angiogenesis ex vivo as there have been conflicting data in the literature on the pro/antiangiogenic effects in various animal models. For example, in an embryonic chick CAM model, b-CD tetradecasulfate administered in conjunction with a steroid was found to inhibit angiogenesis at 100-1000 times the effectiveness of a heparin and steroid combination on a per weight basis [5] . However, in a rabbit cornea model, b-CD tetradecasulfate, when administered alone at very low concentrations (15 mg/mm 3 ; B6 mmol/l), stimulated blood vessel growth and density [5] . Using a subcutaneous plastic sponge model in mice, Strauss et al. [21] observed a dose-dependent effect after intraperitoneal administration of S-b-CDs alone on capillary density, with very low doses (200 ng/mouse; B0.06 mmol/l) apparently promoting angiogenesis whereas 'high' doses (20 mg/mouse; B6 mmol/l) reduced the vessel index in the sponges. S-b-CDs convincingly prevented vessel outgrowth as quantified in the rat aortic ring assay. Furthermore, collagen onplants in chick embryo CAMs containing S-b-CDs prevented the formation of new vasculature within the onplant site, creating an avascular regression zone free of blood vessels. Yadav et al. [39] , who investigated the antiangiogenic effect of curcumin in complexation with nonsulfated b-CDs, defined angiogenesis inhibition as a zone of avascularity, which can be 2-6 mm in diameter, as a result of vessel occlusion or regression. Zones of avascularity observed in response to S-b-CDs and JNJ-10198409 were B2-3 mm in diameter within the central area of the onplant.
Prolonged intravenous administration of S-b-CDs was found to be necessary to produce sustained inhibition of intimal hyperplasia [36] , which is a vascular remodeling and repair process in response to the injury of vascular walls. Intimal hyperplasia is similar to the metastatic cascade as it involves stimulation of the coagulation cascade, and EC and smooth muscle cell migration and proliferation, and is dependent on angiogenic growth factors and selectin interactions [36, 40] . The requirement of prolonged intravenous administration of S-b-CDs may be related to the fact that intravenously administered b-CDs are eliminated rapidly from circulation [41] . Continuous administration of S-b-CDs may therefore be required and, favorably, S-b-CDS have reduced anticoagulant activity as compared with heparins [6] , allowing them to be administered at higher dosages [20, 42] . Importantly, FD(S) allows for the simultaneous intravenous administration of all components, 5-FU, LV, and S-b-CDs, and may improve the outcome for cancer patients by ensuring the continual administration of S-bCDs at high, yet tolerable concentrations.
Finally, the inclusion of therapeutic doses of S-b-CDs in anticancer drug formulations, such as FD(S), offers the potential to limit local invasion and metastases, through the inhibition of angiogenesis, as well as to reduce tumor growth. Together with its useful anticoagulant properties, S-b-CD as a component in anticancer drug formulations should be exploited for the development of a new generation of dual-action therapeutics with potential for improved survival outcomes for cancer patients.
